Dashboard
Strong Long Term Fundamental Strength with a 108.34% CAGR growth in Operating Profits
Healthy long term growth as Net Sales has grown by an annual rate of 71.70% and Operating profit at 108.34%
The company has declared Positive results for the last 6 consecutive quarters
Technical trend is Sideways signifying no clear price momentum
With ROE of 13.3, it has a Expensive valuation with a 5 Price to Book Value
Majority shareholders : Promoters
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
INR 5,126 Cr (Small Cap)
37.00
40
0.00%
0.32
13.31%
5.16
Total Returns (Price + Dividend) 
Senores Pharma. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Senores Pharmaceuticals Ltd Faces Mixed Technical Signals Amid Price Momentum Shift
Senores Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish trend to a sideways pattern. This change is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a period of consolidation after recent volatility.
Read More
Senores Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
Senores Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Despite a recent dip in price, the stock’s technical indicators present a complex picture, with some metrics signalling caution while others suggest potential for moderate upside. Investors and analysts are closely monitoring these developments amid a backdrop of strong year-to-date returns and evolving market dynamics.
Read More
Senores Pharmaceuticals Ltd is Rated Hold by MarketsMOJO
Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 November 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.
Read More Announcements 
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
18-Nov-2026 | Source : BSESenores Pharmaceuticals Limited has informed the Exchange regarding the Scrutinizer Report dated November 17 2026
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
18-Nov-2026 | Source : BSESenores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Postal Ballot
Regulation 30 Disclosure Regarding Issuance Of Certificate Of GMP Compliance By The State Service Of Ukraine On Medicines And Drugs Control
17-Nov-2026 | Source : BSEWe are pleased to announce that the manufacturing facility of our Subsidiary Company. Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification by the State service of Ukraine on Medicines and Drugs Control.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
2.8104
Held by 11 Schemes (7.36%)
Held by 41 FIIs (6.01%)
Swapnil Jatin Shah (7.72%)
Hsbc Mutual Fund - Hsbc Multi Cap Fund (2.87%)
29.39%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 6.73% vs 2.87% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 28.55% vs -2.82% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Nine Monthly Results Snapshot (Standalone) - Dec'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 58.85% vs 85.65% in Mar 2025
YoY Growth in year ended Mar 2026 is 96.99% vs 86.20% in Mar 2025